Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(42.9%)

N/A

3(42.9%)

Early Phase 1

1(14.3%)

7Total

Phase 1(3)

N/A(3)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05642429Phase 1Active Not Recruiting

Study of AV-1959D, an Amyloid Beta Vaccine

Role: lead

NCT07142278Phase 1Not Yet Recruiting

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Role: collaborator

NCT07158905Phase 1Not Yet Recruiting

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

Role: lead

NCT05043701Early Phase 1Recruiting

Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma

Role: collaborator

NCT03973203Not ApplicableCompleted

Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients

Role: collaborator

NCT04538521Not ApplicableCompleted

NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients

Role: collaborator

NCT03650127Unknown

Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study

Role: collaborator

NCT03288389Not ApplicableSuspended

Membrane Lipid Replacement in Fibromyalgia

Role: lead

NCT04037150Unknown

Circulating DNA in Surgically Treated NSCLC

Role: collaborator

All 9 trials loaded